{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:58:24Z","timestamp":1791248304145,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41433-026-04425-0","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:57:57Z","timestamp":1776142677000},"page":"1351-1357","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Early real-world outcomes of aflibercept 8\u2009mg in previously treated neovascular age-related macular degeneration"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0755-7242","authenticated-orcid":false,"given":"Imran Karim","family":"Janmohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Havena","family":"Harahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3820-5812","authenticated-orcid":false,"given":"Barnaby","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh","family":"Sahbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman","family":"Farahat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabeeba","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Membrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"4425_CR1","doi-asserted-by":"crossref","unstructured":"Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Heal. 2014;2:e106\u201316. Available from: https:\/\/www.thelancet.com\/action\/showFullText?pii=S2214109X13701451","DOI":"10.1016\/S2214-109X(13)70145-1"},{"key":"4425_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2023.26074","volume":"331","author":"M Fleckenstein","year":"2024","unstructured":"Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. Age-related macular degeneration: a review. JAMA. 2024;331:147\u201357.","journal-title":"JAMA"},{"key":"4425_CR3","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432\u201344.","journal-title":"N Engl J Med"},{"key":"4425_CR4","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537\u201348.","journal-title":"Ophthalmology"},{"key":"4425_CR5","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729\u201340.","journal-title":"Lancet"},{"key":"4425_CR6","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1097\/IAE.0000000000002670","volume":"40","author":"FG Holz","year":"2020","unstructured":"Holz FG, Figueroa MS, Bandello F, Yang Y, Ohji M, Dai H, et al. Ranibizumab treatment in treatment-naive neovascular age-related macular degeneration: results from Luminous, a global real-world study. Retina. 2020;40:1673\u201385.","journal-title":"Retina"},{"key":"4425_CR7","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.oret.2025.02.002","volume":"9","author":"S Bala","year":"2025","unstructured":"Bala S, Barbosa GCS, Mohan N, Srivastava SK, Kaiser PK, Sastry A, et al. Initial functional and anatomical outcomes of high-dose aflibercept 8 mg in exudative neovascular age-related macular degeneration. Ophthalmol Retina. 2025;9:756\u201366.","journal-title":"Ophthalmol Retina"},{"key":"4425_CR8","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403:1141\u201352.","journal-title":"Lancet"},{"key":"4425_CR9","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1038\/s41433-024-03312-w","volume":"38","author":"JF Korobelnik","year":"2024","unstructured":"Korobelnik JF, Lanzetta P, Wykoff CC, Wong TY, Zhang X, Morgan-Warren P, et al. Sustained disease control with aflibercept 8 mg: a new benchmark in the management of retinal neovascular diseases. Eye. 2024;38:3218\u201321.","journal-title":"Eye"},{"key":"4425_CR10","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","volume":"141","author":"CC Wykoff","year":"2023","unstructured":"Wykoff CC, Brown DM, Reed K, Berliner AJ, Gerstenblith AT, Breazna A, et al. Effect of high-dose intravitreal aflibercept, 8 mg, in patients with neovascular age-related macular degeneration: the phase 2 CANDELA randomized clinical trial. JAMA Ophthalmol. 2023;141:834\u201342.","journal-title":"JAMA Ophthalmol"},{"key":"4425_CR11","doi-asserted-by":"crossref","unstructured":"Abu Ishkheidem I, Inci E, Breimer M, Silfversw\u00e4rd ST, Zetterberg M, Gr\u00f6nlund MA. Real-world outcomes of aflibercept 8 mg in patients previously treated for neovascular age-related macular degeneration. Acta Ophthalmol. 2025. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/40922455\/","DOI":"10.1111\/aos.17590"},{"key":"4425_CR12","doi-asserted-by":"crossref","unstructured":"Musadiq M, Musadiq M, Latif F, Ng B, Azzopardi M, Gilead N, et al. Early real-world outcomes of switching to 8 mg aflibercept for neovascular age-related macular degeneration in the United Kingdom. Life. 2025;15:903. Available from: https:\/\/www.mdpi.com\/2075-1729\/15\/6\/903\/htm","DOI":"10.3390\/life15060903"},{"key":"4425_CR13","unstructured":"Drug approval package: EYLEA HD. 2025. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/761355Orig1s000TOC.cfm"},{"key":"4425_CR14","unstructured":"Vabysmo | European Medicines Agency (EMA). 2024. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vabysmo"},{"key":"4425_CR15","unstructured":"MHRA approves faricimab through international work-sharing initiative\u2014GOV.UK. 2024. Available from: https:\/\/www.gov.uk\/government\/news\/mhra-approves-faricimab-through-international-work-sharing-initiative"},{"key":"4425_CR16","unstructured":"Genentech: Press Releases. 2022. Available from: https:\/\/www.gene.com\/media\/press-releases\/14943\/2022-01-28\/fda-approves-genentechs-vabysmo-the-firs?sf159058256=1"},{"key":"4425_CR17","doi-asserted-by":"publisher","unstructured":"Goodchild C, Bailey C, Soto Hernaez J, Ahmed E, Salvatore S. Real-world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapy. Eye. 2024;3\u20138. Available from: https:\/\/doi.org\/10.1038\/s41433-024-03218-7","DOI":"10.1038\/s41433-024-03218-7"},{"key":"4425_CR18","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/s41433-025-03616-5","volume":"39","author":"IK Janmohamed","year":"2025","unstructured":"Janmohamed IK, Mushtaq A, Kabbani J, Harrow S, Nadarajasundaram A, Ata A, et al. 1-Year real-world outcomes of faricimab in previously treated neovascular age-related macular degeneration. Eye. 2025;39:1344\u20138.","journal-title":"Eye"},{"key":"4425_CR19","doi-asserted-by":"crossref","unstructured":"Sim SY, Chalkiadaki E, Koutsocheras G, Nicholson L, Sivaprasad S, Patel PJ, et al. Real-world 1-year outcomes of treatment-intensive neovascular age-related macular degeneration switched to faricimab. Ophthalmol Retina. 2024;9:22\u201330.","DOI":"10.1016\/j.oret.2024.07.020"},{"key":"4425_CR20","doi-asserted-by":"crossref","unstructured":"Sambhara D, Vakharia P, Eichenbaum DA. Real-world efficacy and safety of 8 mg aflibercept in neovascular AMD: a case series. BMJ Open Ophthalmol. 2025;10. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/39947712\/","DOI":"10.1136\/bmjophth-2024-002091"},{"key":"4425_CR21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10384-024-01107-w","volume":"68","author":"H Matsumoto","year":"2024","unstructured":"Matsumoto H, Hoshino J, Numaga S, Mimura K, Asatori Y, Akiyama H. Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration. Jpn J Ophthalmol. 2024;68:531\u20137.","journal-title":"Jpn J Ophthalmol"},{"key":"4425_CR22","doi-asserted-by":"crossref","unstructured":"Sisk RA. Occlusive retinal vasculitis after aflibercept 8mg injection for wet macular degeneration. Retina Cases Brief Rep. 2025. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/40184546\/","DOI":"10.1097\/ICB.0000000000001757"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04425-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04425-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04425-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:54:51Z","timestamp":1781510091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04425-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4425"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04425-0","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"21 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}